Appendix 4E and Annual Report

Aug 19, 2026 at 9:27 PM EDT · Issued by Arovella Therapeutics Limited via ASX

Filed with ASX · Aug 19, 2026 at 9:27 PM EDT

On 6ix: 6ix.com/news/appendix-4e-and-annual-report-215

Appendix 4E Annual Report 30 June 2026 Arovella Therapeutics Limited ABN 35 090 987 250 Arovella Therapeutics Limited Annual Report June 30 2026 APPENDIX 4E Preliminary final report 1. Company details Name of entity: Arovella Therapeutics Limited ABN: 35 090 987 250 Reporting...

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

Notification regarding unquoted securities - ALAAug 16
Investor Webinar PresentationAug 11
Investor Webinar RegistrationAug 11
Quarterly Activities/Appendix 4C Cash Flow ReportJul 26
Arovella Appoints Acting CEOMay 6

Later from Arovella Therapeutics

Appendix 4GAug 19
Corporate Governance StatementAug 19
Clinical manufacturing batch released, first site activatedSep 6
Notification of 2026 AGM DateSep 8
2026 ESG ReportSep 16

All Arovella Therapeutics news releases

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics